Elsevier

Atherosclerosis

Volume 220, Issue 2, February 2012, Pages 287-293
Atherosclerosis

Review
NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages

https://doi.org/10.1016/j.atherosclerosis.2011.08.041Get rights and content

Abstract

Macrophage infiltration into the atherosclerotic lesion is known to play a central role in the initiation of atherosclerosis. In contrast, the role of macrophages during the etiology of non-alcoholic steatohepatitis (NASH) has been considered to be merely a late consequence of steatosis. However, recent insights suggest that macrophage activation and infiltration is also an early initiating event in NASH and thereby point to the shared etiology of atherosclerosis and NASH. In this review, we put forward the hypothesis that NASH and atherosclerosis are actually two aspects of a shared disease, involving the local presence of activated macrophages. We will review the current data supporting the shared mechanisms and also discuss the implications.

Introduction

The term ‘non-alcoholic fatty liver disease’ (NAFLD) is used to describe a variety of liver diseases of different severity, from pure steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis and, rarely, hepatocellular carcinoma [1]. NASH is viewed as the hepatic event of the metabolic syndrome and it is characterized by hepatic triglyceride (TG) accumulation (i.e. steatosis), in combination with hepatic inflammation. In general, the distinction between NASH and NAFLD is difficult to make in human studies, since a liver biopsy is the only golden standard to distinguish simple steatosis from NASH. The importance of NAFLD and its strong relationship with the metabolic syndrome has stimulated interest in the possible role of the liver in the development of cardiovascular diseases (CVD). Indeed, NAFLD patients have a higher risk of death than the general population, mainly due to CVD or liver-related causes [2]. However, the close interrelationships between fatty liver diseases, the metabolic syndrome and atherosclerosis make it extremely difficult to dissect the cause–effect relationship leading to increased CVD risk.

Atherosclerosis is characterized by the thickening and hardening of the arteries and is a main cause of myocardial infarction or stroke, which is the most common reason of death in the Western world [3]. Monocyte recruitment and macrophage maturation accompanied by uptake of modified LDLs via scavenger receptors (e.g. scavenger receptor A and CD36) gives rise to foam cells in the atheroma and is a key event in the formation of the earliest vascular lesions [4]. At later stages of the disease, growth factor released by macrophages in the plaque cause proliferation of smooth muscle cells and the plaque becomes fibrotic. Ruptured plaques usually have a fibrous cap heavily infiltrated by macrophages. These macrophages are activated at the site of plaque disruption and are capable of degrading extracellular matrix by phagocytosis or by stimulating production of metalloproteases, which weaken the fibrous cap and predispose the plaque to rupture [5]. Spontaneous plaque rupture or acute interventions expose active tissue factor, which is found in abundance in atherosclerotic plaques, in the core to circulating blood, triggering thrombosis [6]. These atherogenic processes are thought to be triggered by well identified risk factors, such as hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking [7]. Unlike atherosclerosis, which has a complex multifactor etiology, the etiology of NASH was until recently viewed as a paradigm of “two-hit” model [8]. According to this model, hepatic steatosis is the critical first hit, thereby sensitizing the liver to further insults, leading to hepatic inflammation and further liver damage. Thus, unlike atherosclerosis that is driven by inflammation besides lipid accumulation, the inflammatory response in NASH was considered to be a consequence rather than a cause of the disease according to the two-hit hypothesis [8]. Among the well known examples of lipotoxic cellular injuries that can trigger hepatocytes death and inflammation during NASH is increased fatty acid (FA) oxidation and oxidative stress, alteration of cellular membrane FA and phospholipid composition, alteration of cellular cholesterol content, disturbances in ceramide signaling and direct free FA toxicity [9]. However, while steatosis can lead to inflammation, not every patient with steatosis will further progress into NASH. Therefore, it is thought that the accumulation of excessive TG and the development of hepatic injury occur in parallel but independently. Moreover, recent reports in animal models have raised doubts about steatosis and apoptosis as a necessary precondition for the development of hepatic inflammation, as inflammation can develop very early after a short period of high fat feeding and can develop alongside to steatosis [10], [11]. Instead, an increasing number of studies emphasize the central role of activated macrophages in the early development of NASH and thus proposing a pathophysiological mechanism similar to atherosclerosis. Based on this evidence, we believe that NASH is not merely an early mediator of atherosclerosis but actually another aspect of the same disease.

In this review, we will summarize the current knowledge on the similarity in epidemiology, pathophysiology, diagnosis and therapy of both NASH and atherosclerosis. Based on these similarities, we put forward the hypothesis that NASH and atherosclerosis are actually two aspects of a shared disease, with a common etiology involving the local presence of activated macrophages. In addition, the clinical applications of these similarities will be discussed.

Section snippets

NASH as a risk factor for CVD

Many observations support an association between NAFLD and increased risk of developing CVD. However, since it is relatively difficult to obtain liver biopsies, these studies do not differentiate between simple steatosis and NASH. Thus, very few studies have investigated the direct correlation between hepatic inflammation and atherosclerosis. In addition, although the liver has a critical role in inducing, sustaining and further exacerbating systemic inflammation, it is difficult to estimate

Central role for inflammation in the etiology of CVD and NASH

Macrophages play an essential role during the disease process of atherosclerosis by communicating inflammatory signals among metabolic tissues in response to overnutrition and insulin resistance and by scavenging modified lipids. Macrophages can accumulate large amounts of lipids, transform into foam cells and drive atherogenesis [51], [52], [53], [54]. The same process of accumulation of lipid-loaded macrophages was observed in NASH, where hyperlipidemic mice demonstrated bloated foamy Kupffer

Therapy

The lack of adequately powered randomized controlled trials of sufficient duration and with histological end-points, as well as the lack of a suitable animal model that faithfully recapitulates the pathophysiology of human NASH, are major obstacles in developing therapy for NASH. Thus, a rational treatment for NASH patients is currently absent. Based on the ‘two hit’ model, in which steatosis precedes inflammation, the main focus for therapy is currently aimed at steatosis. However, since

Concluding remarks – NASH and atherosclerosis are two aspects of a shared disease

The association between fatty liver diseases and CVD risk was formulated many years ago. So far, most of the studies did not separate between NAFLD and NASH and therefore did not address the fundamental role of macrophages in both of these diseases. Fortunately, the past few years have brought remarkable advances in our understanding of the pathogenesis NASH, often by the extension of research in the atherosclerosis field. A plethora of these studies indicate that NASH further exacerbates CVD

Acknowledgements

R. Shiri-Sverdlov: Veni: 916.76.070 (2006/00496/MW); Maag Lever Darm Stichting (MLDS) (WO 08-16 + WO 10-65); P.C.N. Rensen: Established Investigator of the Netherlands Heart Foundation (NHS 2009.T038); CTMM, Atherosclerosis NASH.

References (122)

  • G. Musso et al.

    Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

    Hepatology (Baltimore, MD)

    (2003)
  • F.J. Field et al.

    TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2

    Journal of Lipid Research

    (2010)
  • H. Itabe et al.

    Lysosomal accumulation of oxidized phosphatidylcholine-apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein

    Biochimica et Biophysica Acta

    (2000)
  • S. Kayo et al.

    Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction

    American Heart Journal

    (2004)
  • O. James et al.

    Non-alcoholic steatohepatitis: another disease of affluence

    Lancet

    (1999)
  • M.C. Wong et al.

    Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leidenmice

    Atherosclerosis

    (2012)
  • L. Vergnes et al.

    Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression

    The Journal of Biological Chemistry

    (2003)
  • J. Crespo et al.

    Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

    Hepatology (Baltimore, MD)

    (2001)
  • J.W. Haukeland et al.

    Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2

    Journal of Hepatology

    (2006)
  • L. Miele et al.

    Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease

    Translational Research

    (2009)
  • C. Lohmann et al.

    Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets

    Atherosclerosis

    (2009)
  • S. Hammer et al.

    Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function

    Journal of the American College of Cardiology

    (2008)
  • S.K. Satapathy et al.

    Novel treatment modalities for nonalcoholic steatohepatitis

    Trends in Endocrinology and Metabolism

    (2010)
  • K. Wouters et al.

    Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice

    FEBS Letters

    (2010)
  • Y.X Wang et al.

    Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E

    Atherosclerosis

    (2002)
  • C. Fernandez-Miranda et al.

    A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

    Digestive and Liver Disease

    (2008)
  • S.M. Reilly et al.

    PPAR delta as a therapeutic target in metabolic disease

    FEBS Letters

    (2008)
  • M. Ekstedt et al.

    Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

    Journal of Hepatology

    (2007)
  • L.A. Adams et al.

    Recent concepts in non-alcoholic fatty liver disease

    Diabetic Medicine

    (2005)
  • K.J. Moore et al.

    Scavenger receptors in atherosclerosis: beyond lipid uptake

    Arteriosclerosis, Thrombosis, and Vascular Biology

    (2006)
  • M.B. Taubman et al.

    Tissue factor in the pathogenesis of atherosclerosis

    Thrombosis and Haemostasis

    (1997)
  • G.K. Hansson et al.

    Inflammation and atherosclerosis

    Annual Review of Pathology

    (2006)
  • H. Malhi et al.

    Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease

    Seminars in Liver Disease

    (2008)
  • B. Gustafson et al.

    Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis

    Arteriosclerosis, Thrombosis, and Vascular Biology

    (2007)
  • M.E. Dumas et al.

    Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

    Proceedings of the National Academy of Sciences of the United States of America

    (2006)
  • Z. Wang et al.

    Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

    Nature

    (2011)
  • A.G. Pittas et al.

    Adipocytokines and insulin resistance

    The Journal of Clinical Endocrinology and Metabolism

    (2004)
  • L. Miele et al.

    Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

    Hepatology (Baltimore, MD)

    (2009)
  • L.F. Van Gaal et al.

    Mechanisms linking obesity with cardiovascular disease

    Nature

    (2006)
  • S.E. Shoelson et al.

    Inflammation and insulin resistance

    The Journal of Clinical Investigation

    (2006)
  • M. Yoneda et al.

    High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH

    Journal of Gastroenterology

    (2007)
  • G. Targher et al.

    NASH predicts plasma inflammatory biomarkers independently of visceral fat in men

    Obesity (Silver Spring, MD)

    (2008)
  • Y. Ikura et al.

    Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression

    Hepatology (Baltimore, MD)

    (2006)
  • N. Villanova et al.

    Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

    Hepatology (Baltimore, MD)

    (2005)
  • R.K. Schindhelm et al.

    Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus

    European Journal of Clinical Investigation

    (2005)
  • O. Senturk et al.

    Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease

    Internal Medicine Journal

    (2008)
  • P.O. Bonetti et al.

    Endothelial dysfunction: a marker of atherosclerotic risk

    Arteriosclerosis, Thrombosis, and Vascular Biology

    (2003)
  • G. Targher et al.

    Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation

    Diabetes Care

    (2004)
  • A. Brea et al.

    Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study

    Arteriosclerosis, Thrombosis, and Vascular Biology

    (2005)
  • G. Targher et al.

    Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients

    Journal of Endocrinological Investigation

    (2006)
  • Cited by (0)

    View full text